New Delhi, Aug 06, 2020: Convalescent plasma therapy did not show benefit in reducing mortality risk among COVID-19 patients, according to an interim analysis of a randomised controlled trial done at AIIMS, Delhi to assess the efficacy of this mode of treatment.
During the trial, one group of patients was given convalescent plasma therapy along with the standard supportive treatment while the other group only received standard treatment. The number of fatalities recorded in both the groups was equal and there was not much clinical improvement in the condition of patients, he said.
Meanwhile, Novavax Inc said it has signed a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate. The Indian drugmaker will have exclusive rights for the shot in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those assigned by the World Bank as upper-middle or high-income countries, news agency Reuters reported.